Comment from Biotechnology Innovation Organization (BIO)

Summary: The Biotechnology Innovation Organization (BIO) supports the FDA's pilot program for AI-enabled optimization of early-phase clinical trials, commending the effort to streamline development. They recommend a focused, safety-oriented framework that prioritizes regulatory oversight, clear data definitions, and transparent governance to ensure the pilot provides actionable and scalable learnings for the industry.